{"id":"adjuvant-immunotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (fatigue, fever, rash)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lymphopenia"}]},"_chembl":{"chemblId":"CHEMBL4650400","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adjuvant immunotherapy is administered following surgery, chemotherapy, or radiation to boost anti-tumor immune responses and reduce recurrence risk. It typically works by activating T cells, enhancing checkpoint inhibition, or promoting dendritic cell-based immunity to target micrometastatic disease that may persist after initial treatment.","oneSentence":"Adjuvant immunotherapy enhances the body's immune system to recognize and eliminate residual cancer cells after primary treatment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:59:50.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment in cancer patients (specific cancer type and stage under investigation in phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT06498635","phase":"PHASE3","title":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-01","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":306},{"nctId":"NCT06366490","phase":"PHASE1","title":"Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"PhotonPharma, Inc.","startDate":"2026-02-12","conditions":"Ovarian Cancer, Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer","enrollment":8},{"nctId":"NCT07496190","phase":"PHASE2","title":"Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":59},{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT05642195","phase":"PHASE1, PHASE2","title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":188},{"nctId":"NCT06732401","phase":"PHASE3","title":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-07","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":630},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":"Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":1210},{"nctId":"NCT04432207","phase":"PHASE1","title":"A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2020-11-30","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV","enrollment":24},{"nctId":"NCT06008977","phase":"NA","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AdventHealth Translational Research Institute","startDate":"2024-06-03","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":12},{"nctId":"NCT06805305","phase":"PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2025-03-17","conditions":"Glioblastoma (GBM)","enrollment":180},{"nctId":"NCT05987241","phase":"PHASE2, PHASE3","title":"Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-02","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma","enrollment":992},{"nctId":"NCT07489066","phase":"PHASE2","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-01","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC)","enrollment":120},{"nctId":"NCT07486687","phase":"PHASE3","title":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2026-04","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer","enrollment":1000},{"nctId":"NCT07027124","phase":"PHASE2","title":"Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03-19","conditions":"Prostate Cancer, High-risk Prostate Cancer","enrollment":40},{"nctId":"NCT04573140","phase":"PHASE1","title":"A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2021-12-13","conditions":"Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma","enrollment":28},{"nctId":"NCT05232916","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects","status":"RECRUITING","sponsor":"Greenwich LifeSciences, Inc.","startDate":"2022-08-11","conditions":"Breast Cancer","enrollment":750},{"nctId":"NCT06931717","phase":"PHASE3","title":"A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy","status":"RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2026-01-12","conditions":"Non-Small Cell Lung Cancer","enrollment":390},{"nctId":"NCT07083479","phase":"","title":"Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma","status":"AVAILABLE","sponsor":"Elicio Therapeutics","startDate":"","conditions":"Pancreatic Ductal Adenocarcinoma, KRAS G12D, KRAS G12V","enrollment":""},{"nctId":"NCT05726864","phase":"PHASE1, PHASE2","title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elicio Therapeutics","startDate":"2023-04-14","conditions":"Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D","enrollment":158},{"nctId":"NCT06133517","phase":"PHASE2","title":"PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para el Progreso de la Oncología en Cantabria","startDate":"2025-01-20","conditions":"Urothelial Bladder Carcinoma","enrollment":70},{"nctId":"NCT06863311","phase":"PHASE2","title":"Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC","status":"RECRUITING","sponsor":"Karie Runcie","startDate":"2026-03-13","conditions":"Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":70},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT03732677","phase":"PHASE3","title":"Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-16","conditions":"Muscle Invasive Bladder Cancer","enrollment":1063},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT07471165","phase":"PHASE2","title":"A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Locally Advanced Perihilar Cholangiocarcinoma","enrollment":25},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT05819892","phase":"PHASE1","title":"Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-07-17","conditions":"Endometrial Cancer","enrollment":21},{"nctId":"NCT07280741","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-02","conditions":"Autoimmune Rheumatic Diseases","enrollment":200},{"nctId":"NCT05660408","phase":"PHASE1, PHASE2","title":"RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-03-12","conditions":"Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma","enrollment":36},{"nctId":"NCT07457099","phase":"","title":"Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2026-04-01","conditions":"Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma","enrollment":85},{"nctId":"NCT06488482","phase":"PHASE3","title":"Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2024-12-19","conditions":"High-risk Melanoma","enrollment":1792},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT02362594","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-16","conditions":"Melanoma","enrollment":1019},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT06275360","phase":"PHASE2","title":"Repositioning Immunotherapy in VetArans With Lung Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-03-01","conditions":"Non-Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT07049055","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","status":"RECRUITING","sponsor":"Engeneic Pty Limited","startDate":"2026-01-12","conditions":"Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":144},{"nctId":"NCT04270149","phase":"PHASE1","title":"Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herbert Lyerly","startDate":"2020-09-01","conditions":"Breast Cancer","enrollment":8},{"nctId":"NCT04990726","phase":"","title":"Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-12-05","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","enrollment":126},{"nctId":"NCT07427186","phase":"NA","title":"Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage Cancer","status":"NOT_YET_RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2026-04-15","conditions":"Solid Cancers","enrollment":600},{"nctId":"NCT07430202","phase":"PHASE1","title":"A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05","conditions":"Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))","enrollment":27},{"nctId":"NCT06622434","phase":"PHASE1, PHASE2","title":"New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-11-08","conditions":"Newly Diagnosed Glioblastoma","enrollment":35},{"nctId":"NCT04526730","phase":"PHASE2","title":"Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-12-22","conditions":"Melanoma","enrollment":17},{"nctId":"NCT07149363","phase":"PHASE2","title":"Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2026-02","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":65},{"nctId":"NCT07230613","phase":"PHASE2","title":"Neo-adjuvant Immunotherapy in Patients With Localized Melanoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2026-01-12","conditions":"Cutaneous Melanoma, Stage III, Mucosal Melanoma","enrollment":50},{"nctId":"NCT06656598","phase":"PHASE2","title":"Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-11-07","conditions":"Stage III NSCLC","enrollment":152},{"nctId":"NCT07400302","phase":"PHASE2","title":"Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2026-02-01","conditions":"Mucosal Melanoma, PD-L1 Positive","enrollment":220},{"nctId":"NCT07262489","phase":"PHASE2","title":"Neo-adjuvant Immunotherapy Master Trial for Localized Cancers","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2026-01-21","conditions":"Localized Cancer","enrollment":200},{"nctId":"NCT03686202","phase":"PHASE2, PHASE3","title":"Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2018-11-30","conditions":"All Solid Tumors","enrollment":65},{"nctId":"NCT07392320","phase":"PHASE2","title":"A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-04","conditions":"Nasopharangeal Cancer","enrollment":142},{"nctId":"NCT07227636","phase":"PHASE2","title":"A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-11-07","conditions":"Colorectal Cancer, Rectal Cancer","enrollment":284},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":22},{"nctId":"NCT03141359","phase":"PHASE2","title":"Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2017-05-12","conditions":"Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer","enrollment":61},{"nctId":"NCT05236114","phase":"","title":"GEMINI-NSCLC: NSCLC Biomarker Study","status":"RECRUITING","sponsor":"Tempus AI","startDate":"2022-06-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1200},{"nctId":"NCT05418972","phase":"PHASE2","title":"A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2023-08-14","conditions":"Stage II Melanoma","enrollment":20},{"nctId":"NCT05488626","phase":"NA","title":"Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer","status":"WITHDRAWN","sponsor":"Varian, a Siemens Healthineers Company","startDate":"2022-10-20","conditions":"Stage III Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03727880","phase":"PHASE2","title":"Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Lei Zheng","startDate":"2019-06-04","conditions":"Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma","enrollment":28},{"nctId":"NCT03867084","phase":"PHASE3","title":"Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-28","conditions":"Hepatocellular Carcinoma","enrollment":959},{"nctId":"NCT07385079","phase":"PHASE3","title":"Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer","enrollment":412},{"nctId":"NCT07371234","phase":"PHASE2","title":"Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Xiwei XU","startDate":"2025-12-15","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":22},{"nctId":"NCT07381075","phase":"PHASE2","title":"A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":120},{"nctId":"NCT06484491","phase":"NA","title":"IMPT Dose Escalation for NSCLC (HyDose)","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2025-09-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":87},{"nctId":"NCT07371611","phase":"PHASE3","title":"Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Qunxing Li,MD","startDate":"2026-01-01","conditions":"Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)","enrollment":104},{"nctId":"NCT07371247","phase":"EARLY_PHASE1","title":"Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy","status":"ENROLLING_BY_INVITATION","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-20","conditions":"Esophageal Cancer, MRD, ctDNA","enrollment":65},{"nctId":"NCT07369882","phase":"NA","title":"Comparison of Efficacy Between De-escalated Surgery and Standard Surgery After Neoadjuvant Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Qunxing Li,MD","startDate":"2026-01-12","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT06599619","phase":"","title":"Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi","status":"RECRUITING","sponsor":"John Kirkwood","startDate":"2025-02-20","conditions":"Melanoma","enrollment":30},{"nctId":"NCT06481813","phase":"NA","title":"Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-12-10","conditions":"Lung Cancer, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma","enrollment":730},{"nctId":"NCT04630730","phase":"PHASE2","title":"Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2022-06-24","conditions":"Bladder Cancer","enrollment":46},{"nctId":"NCT07353437","phase":"PHASE2","title":"Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-31","conditions":"Breast Cancer","enrollment":334},{"nctId":"NCT07351487","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-25","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":37},{"nctId":"NCT03313206","phase":"PHASE2","title":"Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-05-28","conditions":"Head and Neck Mucosal Melanomas","enrollment":60},{"nctId":"NCT02296684","phase":"PHASE2","title":"Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-03-25","conditions":"Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck","enrollment":67},{"nctId":"NCT06682195","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-10-09","conditions":"TNBC, Triple Negative Breast Cancer","enrollment":35},{"nctId":"NCT05594290","phase":"PHASE2","title":"Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2022-12-07","conditions":"Merkel Cell Carcinoma","enrollment":36},{"nctId":"NCT06155279","phase":"PHASE2","title":"Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2024-11-06","conditions":"Pleural Mesothelioma","enrollment":41},{"nctId":"NCT06816927","phase":"PHASE2","title":"Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-11-28","conditions":"Newly Diagnosed Glioblastoma","enrollment":92},{"nctId":"NCT05002569","phase":"PHASE3","title":"A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2021-10-19","conditions":"Melanoma","enrollment":1093},{"nctId":"NCT07320690","phase":"PHASE3","title":"De-Escalation Surgery After Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2026-01-01","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":356},{"nctId":"NCT06727617","phase":"PHASE2","title":"Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-11-19","conditions":"Cervical Cancers","enrollment":134},{"nctId":"NCT07320105","phase":"PHASE4","title":"Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-01-15","conditions":"Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT07120698","phase":"PHASE2","title":"Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)","status":"RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-11-05","conditions":"NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages","enrollment":115},{"nctId":"NCT07317960","phase":"PHASE1","title":"Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic Rhinitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kazakh National Agrarian University","startDate":"2025-11-22","conditions":"Allergic Rhinitis Due to Artemisia Pollen","enrollment":30},{"nctId":"NCT03844750","phase":"PHASE2","title":"Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases","status":"TERMINATED","sponsor":"Chloe Atreya, MD, PhD","startDate":"2019-07-22","conditions":"Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8","enrollment":6},{"nctId":"NCT06120374","phase":"","title":"Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2022-01-01","conditions":"Urothelial Carcinoma","enrollment":178},{"nctId":"NCT05380713","phase":"PHASE2","title":"......SMARTEST Trial......","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2022-05-03","conditions":"Mesothelioma, Malignant","enrollment":30},{"nctId":"NCT07307456","phase":"PHASE2","title":"Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-12-08","conditions":"Bladder Cancer","enrollment":31},{"nctId":"NCT00002968","phase":"PHASE3","title":"Edrecolomab in Treating Patients With Stage II Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1997-05","conditions":"Mucinous Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Colon, Stage IIA Colon Cancer","enrollment":2100},{"nctId":"NCT06949410","phase":"PHASE1","title":"HER2 Vaccine for Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Pravin T.P Kaumaya","startDate":"2026-03","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":36},{"nctId":"NCT04960709","phase":"PHASE3","title":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-08-05","conditions":"Muscle Invasive Bladder Cancer","enrollment":712},{"nctId":"NCT07167160","phase":"PHASE2","title":"Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial","status":"RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-03-10","conditions":"Cervical Cancer, Immunochemotherapy","enrollment":59},{"nctId":"NCT04658147","phase":"PHASE1","title":"Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-05-28","conditions":"Hepatocellular Carcinoma","enrollment":31},{"nctId":"NCT05860296","phase":"PHASE1, PHASE2","title":"Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","status":"TERMINATED","sponsor":"SignalChem Lifesciences Corporation","startDate":"2023-05-31","conditions":"Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic","enrollment":36},{"nctId":"NCT04966663","phase":"PHASE2","title":"Using ctDNA to Determine Therapies for Lung Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-03-28","conditions":"Non Small Cell Lung Cancer, Complete Surgical Resection, Circulating Tumor DNA","enrollment":66},{"nctId":"NCT06411691","phase":"PHASE1","title":"KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-06-24","conditions":"Colorectal Cancer, Pancreatic Cancer","enrollment":54},{"nctId":"NCT07285434","phase":"EARLY_PHASE1","title":"Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT06794775","phase":"PHASE3","title":"SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma","status":"RECRUITING","sponsor":"Hildur Helgadottir","startDate":"2025-07-10","conditions":"Malignant Melanoma Stage III","enrollment":128},{"nctId":"NCT05595408","phase":"","title":"Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2022-02-01","conditions":"Muscle Invasive Upper Tract Urothelial Carcinoma","enrollment":84},{"nctId":"NCT06353906","phase":"PHASE2","title":"Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-08-13","conditions":"Urologic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases","enrollment":27},{"nctId":"NCT07264647","phase":"PHASE2","title":"Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2025-03-27","conditions":"Stage III NSCLC","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1289,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["postoperative adjuvant immunotherapy"],"phase":"phase_3","status":"active","brandName":"Adjuvant immunotherapy","genericName":"Adjuvant immunotherapy","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adjuvant immunotherapy enhances the body's immune system to recognize and eliminate residual cancer cells after primary treatment. Used for Adjuvant treatment in cancer patients (specific cancer type and stage under investigation in phase 3 trial).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}